News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017

UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System

Image-guided system for intensity modulated radiotherapy used on 80-year-old male with head and neck cancer

UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System

October 25, 2017 — Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven (UZ Leuven) in Belgium. Halcyon is an advanced cancer treatment system that is more comfortable for the patient while delivering ease-of-use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training and automated radiation therapy treatment.

Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), according to Varian, and is designed to expand the availability of high-quality cancer care globally. It is well-suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head and neck, and many other forms of cancer.

"We selected the Halcyon system because of its potential to accelerate the treatment workflow and allow for a much closer connection between the patient and therapist," said Prof. Karin Haustermans, M.D., chair of the department, UZ Leuven. "Having now completed our first treatments I can say that Halcyon lived up to its promise of a more efficient workflow and better integration of imaging and treatment, which resulted in a much faster overall treatment time."

For more information: www.varian.com

Related Content

Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 — 

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab.

Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab. Image courtesy of Ludwig Cancer Research

News | Radiation Therapy | January 28, 2021
January 28, 2021 — A study led by Ludwig Chicago